MPI DTPA KIT - CHELATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MPI DTPA KIT - CHELATE (MPI DTPA KIT - CHELATE).
DTPA (diethylenetriaminepentaacetic acid) chelates paramagnetic metal ions (e.g., gadolinium) to form stable complexes that alter T1 relaxation times during MRI, enhancing contrast.
| Metabolism | Not metabolized; eliminated unchanged via glomerular filtration (renal excretion) with an elimination half-life of approximately 1.5-2 hours in patients with normal renal function. |
| Excretion | Renal excretion accounts for >95% of the administered dose via glomerular filtration; less than 2% is excreted in feces. |
| Half-life | The terminal elimination half-life is approximately 1.7 hours in patients with normal renal function (creatinine clearance >80 mL/min); prolonged to >20 hours in severe renal impairment. |
| Protein binding | Negligible (<5%); primarily binds to albumin with very low affinity. |
| Volume of Distribution | 0.2-0.3 L/kg, confined to extracellular fluid space. |
| Bioavailability | 100% following intravenous administration; not bioavailable via oral route. |
| Onset of Action | Rapid renal uptake within 1-2 minutes post-intravenous injection; peak renal activity at 3-5 minutes. |
| Duration of Action | Functional imaging window of 30-60 minutes post-injection for renal scintigraphy; agent is cleared sufficiently by 2-4 hours for repeat studies. |
Adult: 3-4 mCi (111-148 MBq) intravenously as a single dose for renal imaging.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for diagnostic use; drug is excreted renally but radiation exposure is minimal. |
| Liver impairment | No dose adjustment required; hepatic impairment does not affect pharmacokinetics. |
| Pediatric use | Pediatric: 0.1 mCi/kg (3.7 MBq/kg) intravenously, minimum 1 mCi (37 MBq). |
| Geriatric use | No specific adjustment; use lowest effective dose due to potential age-related renal function decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MPI DTPA KIT - CHELATE (MPI DTPA KIT - CHELATE).
| Breastfeeding | Tc-99m DTPA is excreted into breast milk. The estimated radiation dose to a nursing infant is low. American Academy of Pediatrics considers compatible with breastfeeding. M/P ratio not established. Interrupt breastfeeding for 4-6 hours post-injection and discard expressed milk. Resume after clearance. |
| Teratogenic Risk | MPI DTPA KIT (pentetate calcium trisodium) is a technetium-99m chelating agent. No adequate human studies; limited animal data suggest low risk. In pregnancy, radiopharmaceuticals should only be used if benefit justifies potential risk. First trimester: avoid unless essential; second and third trimesters: use if necessary, considering radiation dose to fetus (estimated <0.5 mGy per administration). |
■ FDA Black Box Warning
Not available (no FDA boxed warning for DTPA chelate; however, gadolinium-based contrast agents carry warnings for nephrogenic systemic fibrosis in patients with acute/chronic severe renal insufficiency).
| Common Effects | Thinning of skin Increased risk of infection Reduction in bone density Weight gain Mood changes Upset stomach Behavioral changes |
| Serious Effects |
["Known hypersensitivity to DTPA or any component.","Chronic severe renal impairment (GFR < 30 mL/min/1.73 m²) or acute kidney injury due to risk of NSF (unless imaging is essential and no alternative available).","Intrathecal administration."]
| Precautions | ["Risk of nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal impairment (GFR < 30 mL/min/1.73 m²).","Monitor renal function before administration.","Use lowest dose necessary for adequate imaging.","May cause hypersensitivity reactions, including anaphylaxis.","Do not administer intrathecally (risk of neurotoxicity)."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal vital signs and for hypersensitivity reactions. Fetal monitoring not routinely required but consider fetal radiation dose estimation if repeated use. Document indication and justification for use in pregnancy. |
| Fertility Effects | No known effects on fertility from DTPA chelate itself. Radiopharmaceutical radiation may theoretically affect gonadal tissue, but single diagnostic dose (typically <10 mSv) is unlikely to impair fertility. |